Cyclic peptide binder against oncogenic K-Ras
Cyclic peptides represented by (Formula 1) selectively bind the oncoprotein K-Ras G12D in vitro and in cellulo, where Z1 and Z2 are each L-propargylglycine (Pra), azidoornithine (OrnN3), or L-azidolysine (Az4), and V1-V2-V3-V4-V5 is an amino acid variable region having a sequence selected from the group consisting of SEQ ID NOs: 1-20.
1. A cyclic peptide represented by Formula I:
wherein: Z1 and Z2 are each L-propargylglycine (Pra), azidoornithine (OrnN3), or L-azidolysine (Az4), wherein when Z1 is Pra, Z2 is OrnN3 or Az4, when Z1 is OrnN3 or Az4, Z2 is Pra; and V1-V2-V3-V4-V5 is a five amino acid variable region having a sequence selected from the group consisting of SEQ ID NOs: 1-20; L is a linker moiety; and B m is an optional detection group, wherein m is 0 or 1.
2. The cyclic peptide of claim 1 , wherein Z1 is Pra and Z2 is Az4.
3. The cyclic peptide of claim 1 , wherein Z1 is Pra and Z2 is OrnN3.
4. The cyclic peptide of claim 1 , wherein Z1 is Az4 and Z2 is Pra.
5. The cyclic peptide of claim 1 , wherein V1-V2-V3-V4-V5 is SEQ ID NO: 7, 11, or 16.
6. The cyclic peptide of claim 1 , wherein L is 1,4-triazole.
7. The cyclic peptide of claim 6 , wherein when m is 1, the optional detection group is a detection tag, a detection tag, or a combination of a spacer group and a detection tag.
8. The cyclic peptide of claim 7 , wherein the spacer group is polyethylene glycol (PEG) or 6-aminohexanoic acid (Ahx).
9. The cyclic peptide of claim 7 , wherein the detection tag is an affinity tag, a fluorescent tag, or a fluorescently labeled affinity tag.
10. The cyclic peptide of claim 7 , wherein the detection tag is an affinity tag selected from the group consisting of biotin, streptavidin, poly-histidine, poly-arginine, FLAG, cyclodextrin, adamantane, and combinations thereof.
11. The cyclic peptide of claim 7 wherein the spacer group is PEG and the detection tag is biotin.